These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8659193)

  • 1. [Local drug administration systems, preclinical and clinical use: perspectives and limitations].
    Gonschior P; Wilensky R; March K; Höfling B
    Z Kardiol; 1996 Mar; 85(3):155-65. PubMed ID: 8659193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Drug Delivery for Restenosis and Thrombosis Ñ Progress?
    Gonschior P
    J Invasive Cardiol; 1998 Oct; 10(8):528-532. PubMed ID: 10762837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of locally delivered conventional drug therapies.
    Camenzind E; Kutryk MJ; Serruys PW
    Semin Interv Cardiol; 1996 Mar; 1(1):67-76. PubMed ID: 9552496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Concepts for local therapy of restenosis].
    Riessen R; Oberhoff M; Karsch KR
    Z Kardiol; 1996; 85 Suppl 1():87-98. PubMed ID: 8882829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug and instrumental therapeutic approaches for prevention of restenosis].
    Höfling B; Huehns TY; Gonschior P; Nikol S
    Z Kardiol; 1995; 84 Suppl 4():151-8. PubMed ID: 8585268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis.
    Herdeg C; Goehring-Frischholz K; Zuern C; Geisler T; Hartmann U; Hoevelborn T; Haase KK; Gawaz M
    Thromb Res; 2008; 123(2):236-43. PubMed ID: 18452977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for local drug delivery.
    Eccleston DS; Horrigan MC; Ellis SG
    Semin Interv Cardiol; 1996 Mar; 1(1):8-16. PubMed ID: 9552480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of biodegradable stents.
    Tanguay JF; Zidar JP; Phillips HR; Stack RS
    Cardiol Clin; 1994 Nov; 12(4):699-713. PubMed ID: 7850839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Standards in interventional therapy of coronary artery disease].
    Rutsch W; Gliech V; Dübel HP; Borges A; Theres H; Laule M; Baumann G
    Herz; 2002 Sep; 27(6):481-501. PubMed ID: 12378393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
    Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
    Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiology and pathobiochemistry of restenosis].
    Höfling B; Gonschior P; Nikol S; Bauriedel G; Welsch U; Nerlich A
    Z Kardiol; 1994 May; 83(5):313-8. PubMed ID: 8053238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local paclitaxel delivery after coronary stenting in an experimental animal model.
    Dommke C; Haase KK; Süselbeck T; Streitner I; Haghi D; Metz J; Borggrefe M; Herdeg C
    Thromb Haemost; 2007 Sep; 98(3):674-80. PubMed ID: 17849059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.
    Birkenhauer P; Yang Z; Gander B
    J Pharm Pharmacol; 2004 Nov; 56(11):1339-56. PubMed ID: 15525440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
    Scheller B; Speck U; Abramjuk C; Bernhardt U; Böhm M; Nickenig G
    Circulation; 2004 Aug; 110(7):810-4. PubMed ID: 15302790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First experience with hybrid percutaneous transmyocardial laser revascularization and angioplasty in patients with lesions at high risk for restenosis: Results of a phase I feasibility study.
    Stone GW; St Goar FG; Taussig A; Power JA; Kosinski E; Shawl F
    Am Heart J; 2001 Oct; 142(4):679-83. PubMed ID: 11579359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.